RE: RE: Shigamabs and E.ColiI think Thallion and potential partners are still arguing about the how each will cut the pie.
Thallion should have gone alone in 2007.
They need something like 30-40 millions to finish the PIII trials.
Seems like a low risk high reward drug. Stable market for E.coli since all US hospitals and clinics will have to stock pile it.
Orphan drug status.
Shigamabs doesn't kill E. Coli bacteria, just renders it harmless. Easy science.
Not sure why things are taking so long.
MontrealFrench you seem to know what's going on with that Arbitration process.
I think Thallion has an easy win as Expergen has been blackmailing us.
232 has been proven efficacious already, it just need a bigger trial size.